<DOC>
	<DOCNO>NCT01726374</DOCNO>
	<brief_summary>High-risk stage 1 NSGCTTs curable careful surveillance follow 3 cycle BEP ( bleomycin , etoposide , cisplatin 500mg/m2 etoposide per cycle ) chemotherapy 40-50 % case experience recurrence . Alternatively , adjuvant chemotherapy 2 cycle BEP ( low dose use advanced disease - etoposide 360mg/m2 ) patient achieve outcome avoids intensive surveillance , deliver 33 % chemotherapy cycle population basis . If single cycle BEP dose use advanced disease similar high rate relapse-free survival ( cure ) see two low dose cycle , would reduce overall burden chemotherapy healthcare resource usage would likely lead change practice globally .</brief_summary>
	<brief_title>Trial 1 Cycle Adjuvant BEP Chemotherapy High Risk , Stage 1 Non-seminomatous Germ Cell Testis Tumours</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms , Germ Cell Embryonal</mesh_term>
	<mesh_term>Testicular Neoplasms</mesh_term>
	<criteria>Histologically proven nonseminomatous germ cell tumour combine GCT ( NSGCT + seminoma ) testis Histologically proven vascular invasion primary tumour testicular vein lymphatics Clinical stage 1 patient ( normal AFP HCG , optimum marker decline approach normal level orchidectomy AND evidence metastasis CT chest , abdomen pelvis ) Men age 16 year Creatinine clearance &gt; 50 ml/min No previous chemotherapy WBC &gt; 1.5 x 10^9/l platelet 100 x 10^9/l Fit receive chemotherapy Able start BEP ( 500 ) chemotherapy part 111 study within 6* week orchidectomy Written inform consent *If unavoidable delay timescale extend 8 week All patient pure seminoma All patient nonseminoma combine NSGCT + seminoma &gt; stage 1 All patient vascular invasion Previous chemotherapy Patients second malignancy except contralateral TIN contralateral germ cell tumour treat orchidectomy subsequent surveillance 3 year Comorbidity preclude safe administration BEP ( 500 ) chemotherapy Patients renal function impairment ( bilirubin &gt; 1.25 x ULN and/or AST &gt; 2 x ULN ) Patients preexist neuropathy Patients pulmonary fibrosis Patients serious illness medical condition incompatible protocol</criteria>
	<gender>Male</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>